ATE358487T1 - Kombination enthaltend cyamemazine und ein atypisches neuroleptikum - Google Patents

Kombination enthaltend cyamemazine und ein atypisches neuroleptikum

Info

Publication number
ATE358487T1
ATE358487T1 AT00988905T AT00988905T ATE358487T1 AT E358487 T1 ATE358487 T1 AT E358487T1 AT 00988905 T AT00988905 T AT 00988905T AT 00988905 T AT00988905 T AT 00988905T AT E358487 T1 ATE358487 T1 AT E358487T1
Authority
AT
Austria
Prior art keywords
cyamemazine
combination containing
atypical neuroleptic
neuroleptic
atypical
Prior art date
Application number
AT00988905T
Other languages
English (en)
Inventor
Michel Dib
Cyrille Leperlier
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE358487T1 publication Critical patent/ATE358487T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Containers Having Bodies Formed In One Piece (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Mechanical Pencils And Projecting And Retracting Systems Therefor, And Multi-System Writing Instruments (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT00988905T 1999-12-10 2000-12-08 Kombination enthaltend cyamemazine und ein atypisches neuroleptikum ATE358487T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9915632A FR2802101B1 (fr) 1999-12-10 1999-12-10 Association de cymemazine et d'un neuroleptique atypique

Publications (1)

Publication Number Publication Date
ATE358487T1 true ATE358487T1 (de) 2007-04-15

Family

ID=9553137

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00988905T ATE358487T1 (de) 1999-12-10 2000-12-08 Kombination enthaltend cyamemazine und ein atypisches neuroleptikum

Country Status (13)

Country Link
US (2) US6720318B2 (de)
EP (1) EP1239861B1 (de)
JP (1) JP5216176B2 (de)
AT (1) ATE358487T1 (de)
AU (1) AU2525201A (de)
CA (1) CA2393523C (de)
CY (1) CY1108053T1 (de)
DE (1) DE60034249T2 (de)
DK (1) DK1239861T3 (de)
ES (1) ES2283341T3 (de)
FR (1) FR2802101B1 (de)
PT (1) PT1239861E (de)
WO (1) WO2001041769A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2850871B1 (fr) 2003-02-07 2006-07-14 Aventis Pharma Sa Application du 2-cyano-10-(2-methyl-3-(methylamino)propyl) phenothiazine ou un sel pharmaceutiquement acceptable comme medicament
CA2513920A1 (en) * 2003-02-07 2004-08-26 Aventis Pharmaceuticals Inc. Application of 2-cyano-10- (2-methyl-3-(methylamino)- propyl)phenothiazine or a pharmaceutically acceptable salt as medicament
WO2006091725A1 (en) * 2005-02-23 2006-08-31 The Silvan S. Tomkins Institute Treatment of anhedonia
FR2898271B1 (fr) * 2006-03-09 2009-01-16 Pierre Fabre Medicament Sa Nouvelle utilisation d'agents antihistaminiques pour le traitement preventif ou procede de syndromes inflammatoires, en particulier ceux declenches par les toga virus.
WO2016202855A1 (en) 2015-06-16 2016-12-22 Basf Se Scr-catalyzed soot filter with integrated lean nox trap catalyst for use in passive selective catalytic reduction

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
DE4127737A1 (de) 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
FR2722099B1 (fr) * 1994-07-11 1996-10-04 Pf Medicament Nouveau produit de combinaison comprenant de la carpipramine et un neuroleptique.
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EG24221A (en) 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
ZA982368B (en) * 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
US6169084B1 (en) 1997-09-30 2001-01-02 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
BR9911068A (pt) * 1998-05-29 2001-02-06 Lilly Co Eli Terapia combinada para tratamento de distúrbios bipolares

Also Published As

Publication number Publication date
DK1239861T3 (da) 2007-07-30
WO2001041769A2 (fr) 2001-06-14
PT1239861E (pt) 2007-06-21
DE60034249T2 (de) 2007-12-20
EP1239861B1 (de) 2007-04-04
CA2393523C (fr) 2010-11-02
EP1239861A2 (de) 2002-09-18
JP2003516355A (ja) 2003-05-13
CA2393523A1 (fr) 2001-06-14
FR2802101B1 (fr) 2003-02-28
US20040167125A1 (en) 2004-08-26
JP5216176B2 (ja) 2013-06-19
US6720318B2 (en) 2004-04-13
WO2001041769A3 (fr) 2002-02-28
US20020183312A1 (en) 2002-12-05
ES2283341T3 (es) 2007-11-01
CY1108053T1 (el) 2013-09-04
DE60034249D1 (de) 2007-05-16
AU2525201A (en) 2001-06-18
US6982262B2 (en) 2006-01-03
FR2802101A1 (fr) 2001-06-15

Similar Documents

Publication Publication Date Title
UA4614S (uk) Флакон під засіб для догляду за тілом
IL152916A0 (en) Heteroaryl-phenyl heterobicyclic factor xa inhibitors
DE60123276D1 (de) Piperazinderivate zur behandlung bakterieller infektionen
AP2003002857A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
MXPA03007140A (es) Derivados de carbolina.
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
DE69925133D1 (de) Pyrrolobenzodiazepine
ZA200203316B (en) New use and novel n-azabicyclo-amide derivatives.
NO20014303D0 (no) JAK-3-inhibitorer for behandling av allergiske lidelser
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
DE60141465D1 (de) Verschluss und Doppelbehälter
EP1769791A3 (de) Therapeutische strategien für die prävention und behandlung der alzeheimer-krankheit
NO20021689D0 (no) 5-rings heterosykliske derivater, fremstilling derav og anvendelse som medikamenter
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
EE200300165A (et) Fenofibraadi ja koensüüm Q10 kombinatsioon endoteeli düsfunktsiooni ravimiseks
DK1736158T3 (da) Anvendel af 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin samt de fysiologiske acceptable salte deraf
EE200300167A (et) Amidoalküülpiperidiini ja -piperasiini derivaadid, neid sisaldav farmatseutiline kompositsioon ningühendite kasutamine närvisüsteemi häirete raviks
DE60009888D1 (de) Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
ZA200309513B (en) Novel heterocyclic derivatives and medicinal use thereof.
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
ATE317849T1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
NO20012106D0 (no) Middel for behandling av benpatobolisme
MXPA03001826A (es) Derivados de arilpiperazina.
DK1212119T3 (da) Anvendelse af cyamemazin ved behandling af brat seponering af benzodiazepiner
GB9802542D0 (en) New use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1239861

Country of ref document: EP